<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<title>A998</title>
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:"Albertus Extra Bold";
	panose-1:2 14 8 2 4 3 4 2 2 4;}
@font-face
	{font-family:Marlett;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:Times;
	panose-1:2 2 6 3 6 4 5 2 3 4;}
@font-face
	{font-family:Albertus;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	background:navy;
	font-size:12.0pt;
	font-family:"Tahoma",sans-serif;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:9.0pt;
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
p.FronterPage, li.FronterPage, div.FronterPage
	{mso-style-name:FronterPage;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Para10pt
	{mso-style-name:Para10pt;
	font-family:"Times New Roman",serif;}
p.PrefileFronterTitle, li.PrefileFronterTitle, div.PrefileFronterTitle
	{mso-style-name:PrefileFronterTitle;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.StylePrefileFronterTitleLeft, li.StylePrefileFronterTitleLeft, div.StylePrefileFronterTitleLeft
	{mso-style-name:"Style PrefileFronterTitle + Left";
	margin-top:0in;
	margin-right:-.2in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:17.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BillHead
	{mso-style-name:BillHead;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillHeading2
	{mso-style-name:BillHeading2;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BillLanguage
	{mso-style-name:BillLanguage;
	font-family:"Times New Roman",serif;
	font-style:italic;}
p.HangingAnAct, li.HangingAnAct, div.HangingAnAct
	{mso-style-name:HangingAnAct;
	mso-style-link:"HangingAnAct Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.HangingAnActChar
	{mso-style-name:"HangingAnAct Char";
	mso-style-link:HangingAnAct;
	letter-spacing:.2pt;}
span.11ptChar
	{mso-style-name:11ptChar;
	font-family:"Times New Roman",serif;}
span.BillHeadUnBold
	{mso-style-name:BillHeadUnBold;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.bpuBill, li.bpuBill, div.bpuBill
	{mso-style-name:bpuBill;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:26.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuHeadSpon, li.bpuHeadSpon, div.bpuHeadSpon
	{mso-style-name:bpuHeadSpon;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.bpuHeadSponChar
	{mso-style-name:bpuHeadSponChar;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuIntro, li.bpuIntro, div.bpuIntro
	{mso-style-name:bpuIntro;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuLegislature, li.bpuLegislature, div.bpuLegislature
	{mso-style-name:bpuLegislature;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:24.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuNormText, li.bpuNormText, div.bpuNormText
	{mso-style-name:bpuNormText;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.bpuReprint, li.bpuReprint, div.bpuReprint
	{mso-style-name:bpuReprint;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:22.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.bpuSponsor, li.bpuSponsor, div.bpuSponsor
	{mso-style-name:bpuSponsor;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.bpuState, li.bpuState, div.bpuState
	{mso-style-name:bpuState;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:32.0pt;
	font-family:"Arial",sans-serif;
	font-weight:bold;}
span.charMarlett
	{mso-style-name:charMarlett;
	font-family:Marlett;}
p.ElevenPt, li.ElevenPt, div.ElevenPt
	{mso-style-name:ElevenPt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPage12pt, li.FronterPage12pt, div.FronterPage12pt
	{mso-style-name:FronterPage12pt;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageBillHeading, li.FronterPageBillHeading, div.FronterPageBillHeading
	{mso-style-name:FronterPageBillHeading;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;}
p.FronterPageNOCAPS, li.FronterPageNOCAPS, div.FronterPageNOCAPS
	{mso-style-name:FronterPageNOCAPS;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	font-size:12.0pt;
	font-family:"Times",serif;}
p.FronterPageTBox2, li.FronterPageTBox2, div.FronterPageTBox2
	{mso-style-name:FronterPageTBox2;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.FronterPageTextBox, li.FronterPageTextBox, div.FronterPageTextBox
	{mso-style-name:FronterPageTextBox;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.FronterSameAs, li.FronterSameAs, div.FronterSameAs
	{mso-style-name:FronterSameAs;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Pg2Footer, li.Pg2Footer, div.Pg2Footer
	{mso-style-name:Pg2Footer;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Style10pt
	{mso-style-name:"Style 10 pt";
	font-family:"Times New Roman",serif;}
p.StyleFronterPage11pt, li.StyleFronterPage11pt, div.StyleFronterPage11pt
	{mso-style-name:"Style FronterPage + 11 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.StyleFronterPageLoweredby3pt, li.StyleFronterPageLoweredby3pt, div.StyleFronterPageLoweredby3pt
	{mso-style-name:"Style FronterPage + Lowered by  3 pt";
	margin:0in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	position:relative;
	top:3.0pt;}
p.StyleFronterSameAsPatternSolid100White, li.StyleFronterSameAsPatternSolid100White, div.StyleFronterSameAsPatternSolid100White
	{mso-style-name:"Style FronterSameAs + Pattern\: Solid \(100%\) \(White\)";
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Style1, li.Style1, div.Style1
	{mso-style-name:Style1;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	text-align:justify;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
span.Whereas
	{mso-style-name:Whereas;
	font-family:"Times New Roman",serif;
	font-variant:small-caps;
	font-weight:bold;}
p.bpuWpGraphic, li.bpuWpGraphic, div.bpuWpGraphic
	{mso-style-name:bpuWpGraphic;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.LeftBrackt
	{mso-style-name:LeftBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.RightBrackt
	{mso-style-name:RightBrackt;
	font-family:"Albertus Extra Bold",sans-serif;
	font-weight:bold;}
span.Superscript
	{mso-style-name:Superscript;
	font-family:"Albertus",sans-serif;
	font-weight:bold;
	vertical-align:super;}
p.sponUdate, li.sponUdate, div.sponUdate
	{mso-style-name:sponUdate;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BoldItal
	{mso-style-name:BoldItal;
	font-weight:bold;
	font-style:italic;}
p.amendfooter, li.amendfooter, div.amendfooter
	{mso-style-name:amendfooter;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.HangingSup, li.HangingSup, div.HangingSup
	{mso-style-name:HangingSup;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.2in;
	margin-bottom:.0001pt;
	text-align:justify;
	text-indent:-.2in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableBottom, li.HangingTableBottom, div.HangingTableBottom
	{mso-style-name:HangingTableBottom;
	margin-top:0in;
	margin-right:1.0in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
p.HangingTableTop, li.HangingTableTop, div.HangingTableTop
	{mso-style-name:HangingTableTop;
	margin-top:0in;
	margin-right:.5in;
	margin-bottom:0in;
	margin-left:.8in;
	margin-bottom:.0001pt;
	text-indent:-.8in;
	line-height:120%;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	letter-spacing:.2pt;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Segoe UI",sans-serif;
	letter-spacing:.2pt;}
.MsoChpDefault
	{font-size:10.0pt;}
 /* Page Definitions */
 @page WordSection1
	{size:8.5in 14.0in;
	margin:1.5in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 14.0in;
	margin:1.5in 113.75pt 1.0in 113.75pt;}
div.WordSection2
	{page:WordSection2;}
@page WordSection3
	{size:8.5in 14.0in;
	margin:1.0in 1.75in 1.2in 2.0in;}
div.WordSection3
	{page:WordSection3;}
-->
</style>

</head>

<body lang=EN-US>

<div class=WordSection1>

<p class=bpuBill><a name=bpuFrontPg></a>ASSEMBLY, No. 998 </p>

<p class=bpuWpGraphic></p>

<p class=bpuState>STATE OF NEW JERSEY</p>

<p class=bpuLegislature>221st LEGISLATURE</p>

<p class=bpuWpGraphic>  </p>

<p class=bpuIntro>PRE-FILED FOR INTRODUCTION IN THE 2024 SESSION</p>

<p class=bpuIntro>&nbsp;</p>

</div>

<span style='font-size:12.0pt;line-height:120%;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:auto'>
</span>

<div class=WordSection2>

<p class=bpuIntro>&nbsp;</p>

<p class=bpuSponsor>Sponsored by:</p>

<p class=bpuSponsor>Assemblywoman  NANCY F. MUNOZ</p>

<p class=bpuSponsor>District 21 (Middlesex, Morris, Somerset and Union)</p>

<p class=bpuSponsor>Assemblywoman  MICHELE MATSIKOUDIS</p>

<p class=bpuSponsor>District 21 (Middlesex, Morris, Somerset and Union)</p>

<p class=bpuSponsor>Assemblywoman  DAWN FANTASIA</p>

<p class=bpuSponsor>District 24 (Morris, Sussex and Warren)</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>&nbsp;</p>

<p class=bpuSponsor>SYNOPSIS</p>

<p class=bpuNormText>     Adds illicit fentanyls to Schedule I in the New
Jersey Controlled Dangerous Substances Act. </p>

<p class=bpuNormText>&nbsp;</p>

<p class=bpuSponsor>CURRENT VERSION OF TEXT </p>

<p class=bpuNormText>     Introduced Pending Technical Review by Legislative
Counsel.</p>

<p class=bpuNormText>   </p>

</div>

<span style='font-size:10.0pt;font-family:"Times New Roman",serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection3>

<p class=HangingAnAct style='line-height:150%'><span class=BillHead>An Act</span><span
class=HangingAnActChar> concerning certain controlled dangerous substances and
amending P.L.1970, c.226.</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     <span class=BillHeading2>Be It
Enacted </span><span class=BillLanguage>by the Senate and General Assembly of
the State of New Jersey:</span></p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     1.    Section 5 of P.L.1970,
c.226 (C.24:21-5)  is amended to read as follows:</p>

<p class=MsoNormal style='line-height:150%'>     5.  Schedule I.</p>

<p class=MsoNormal style='line-height:150%'>     a.     Tests. The director
shall place a substance in Schedule I if he finds that the substance:  (1) has
high potential for abuse; and (2) has no accepted medical use in treatment in
the United States; or lacks accepted safety for use in treatment under medical
supervision.</p>

<p class=MsoNormal style='line-height:150%'>     b.    The controlled dangerous
substances listed in this section are included in Schedule I, subject to any
revision and republishing by the director pursuant to subsection d. of section
3 of P.L.1970, c.226 (C.24:21-3), and except to the extent provided in any
other schedule.</p>

<p class=MsoNormal style='line-height:150%'>     c.     Any of the following
opiates, including their isomers, esters, and ethers, unless specifically
excepted, whenever the existence of such isomers, esters, ethers and salts is
possible within the specific chemical designation:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   Acetylmethadol</p>

<p class=MsoNormal style='line-height:150%'>     (2)   Allylprodine</p>

<p class=MsoNormal style='line-height:150%'>     (3)   Alphacetylmethadol</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Alphameprodine</p>

<p class=MsoNormal style='line-height:150%'>     (5)   Alphamethadol</p>

<p class=MsoNormal style='line-height:150%'>     (6)   Benzethidine</p>

<p class=MsoNormal style='line-height:150%'>     (7)   Betacetylmethadol</p>

<p class=MsoNormal style='line-height:150%'>     (8)   Betameprodine</p>

<p class=MsoNormal style='line-height:150%'>     (9)   Betamethadol</p>

<p class=MsoNormal style='line-height:150%'>     (10)  Betaprodine</p>

<p class=MsoNormal style='line-height:150%'>     (11)  Clonitazene</p>

<p class=MsoNormal style='line-height:150%'>     (12)  Dextromoramide</p>

<p class=MsoNormal style='line-height:150%'>     (13)  Dextrorphan</p>

<p class=MsoNormal style='line-height:150%'>     (14)  Diampromide</p>

<p class=MsoNormal style='line-height:150%'>     (15)  Diethylthiambutene</p>

<p class=MsoNormal style='line-height:150%'>     (16)  Dimenoxadol</p>

<p class=MsoNormal style='line-height:150%'>     (17)  Dimepheptanol</p>

<p class=MsoNormal style='line-height:150%'>     (18)  Dimethylthiambutene</p>

<p class=MsoNormal style='line-height:150%'>     (19)  Dioxaphetyl butyrate</p>

<p class=MsoNormal style='line-height:150%'>     (20)  Dipipanone</p>

<p class=MsoNormal style='line-height:150%'>     (21)  Ethylmethylthiambutene</p>

<p class=MsoNormal style='line-height:150%'>     (22)  Etonitazene</p>

<p class=MsoNormal style='line-height:150%'>     (23)  Etoxeridine</p>

<p class=MsoNormal style='line-height:150%'>     (24)  Furethidine</p>

<p class=MsoNormal style='line-height:150%'>     (25)  Hydroxypethidine</p>

<p class=MsoNormal style='line-height:150%'>     (26)  Ketobemidone</p>

<p class=MsoNormal style='line-height:150%'>     (27)  Levomoramide</p>

<p class=MsoNormal style='line-height:150%'>     (28)  Levophenacylmorphan</p>

<p class=MsoNormal style='line-height:150%'>     (29)  Morpheridine</p>

<p class=MsoNormal style='line-height:150%'>     (30)  Noracymethadol</p>

<p class=MsoNormal style='line-height:150%'>     (31)  Norlevorphanol</p>

<p class=MsoNormal style='line-height:150%'>     (32)  Normethadone</p>

<p class=MsoNormal style='line-height:150%'>     (33)  Norpipanone</p>

<p class=MsoNormal style='line-height:150%'>     (34)  Phenadoxone</p>

<p class=MsoNormal style='line-height:150%'>     (35)  Phenampromide</p>

<p class=MsoNormal style='line-height:150%'>     (36)  Phenomorphan</p>

<p class=MsoNormal style='line-height:150%'>     (37)  Phenoperidine</p>

<p class=MsoNormal style='line-height:150%'>     (38)  Piritramide</p>

<p class=MsoNormal style='line-height:150%'>     (39)  Proheptazine</p>

<p class=MsoNormal style='line-height:150%'>     (40)  Properidine</p>

<p class=MsoNormal style='line-height:150%'>     (41)  Racemoramide</p>

<p class=MsoNormal style='line-height:150%'>     (42)  Trimeperidine.</p>

<p class=MsoNormal style='line-height:150%'>     d.    Any of the following
narcotic substances, their salts, isomers and salts of isomers, unless
specifically excepted, whenever the existence of such salts, isomers and salts
of isomers is possible within the specific chemical designation:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   Acetorphine</p>

<p class=MsoNormal style='line-height:150%'>     (2)   Acetylcodone</p>

<p class=MsoNormal style='line-height:150%'>     (3)   Acetyldihydrocodeine</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Benzylmorphine</p>

<p class=MsoNormal style='line-height:150%'>     (5)   Codeine methylbromide</p>

<p class=MsoNormal style='line-height:150%'>     (6)   Codeine-N-Oxide</p>

<p class=MsoNormal style='line-height:150%'>     (7)   Cyprenorphine</p>

<p class=MsoNormal style='line-height:150%'>     (8)   Desomorphine</p>

<p class=MsoNormal style='line-height:150%'>     (9)   Dihydromorphine</p>

<p class=MsoNormal style='line-height:150%'>     (10)  Etorphine</p>

<p class=MsoNormal style='line-height:150%'>     (11)  Heroin</p>

<p class=MsoNormal style='line-height:150%'>     (12)  Hydromorphinol</p>

<p class=MsoNormal style='line-height:150%'>     (13)  Methyldesorphine</p>

<p class=MsoNormal style='line-height:150%'>     (14)  Methylhydromorphine</p>

<p class=MsoNormal style='line-height:150%'>     (15)  Morphine methylbromide</p>

<p class=MsoNormal style='line-height:150%'>     (16)  Morphine methylsulfonate</p>

<p class=MsoNormal style='line-height:150%'>     (17)  Morphine-N-Oxide</p>

<p class=MsoNormal style='line-height:150%'>     (18)  Myrophine</p>

<p class=MsoNormal style='line-height:150%'>     (19)  Nicocodeine</p>

<p class=MsoNormal style='line-height:150%'>     (20)  Nicomorphine</p>

<p class=MsoNormal style='line-height:150%'>     (21)  Normorphine</p>

<p class=MsoNormal style='line-height:150%'>     (22)  Phoclodine</p>

<p class=MsoNormal style='line-height:150%'>     (23)  Thebacon.</p>

<p class=MsoNormal style='line-height:150%'>     e.     Any material, compound,
mixture or preparation which contains any quantity of the following
hallucinogenic substances, their salts, isomers and salts of isomers, unless
specifically excepted, whenever the existence of such salts, isomers, and salts
of isomers is possible within the specific chemical designation:</p>

<p class=MsoNormal style='line-height:150%'>     (1)   3,4-methylenedioxy
amphetamine</p>

<p class=MsoNormal style='line-height:150%'>     (2)   5-methoxy-3,4-methylenedioxy
amphetamine</p>

<p class=MsoNormal style='line-height:150%'>     (3)   3,4,5-trimethoxy
amphetamine</p>

<p class=MsoNormal style='line-height:150%'>     (4)   Bufotenine</p>

<p class=MsoNormal style='line-height:150%'>     (5)   Diethyltryptamine</p>

<p class=MsoNormal style='line-height:150%'>     (6)   Dimethyltryptamine</p>

<p class=MsoNormal style='line-height:150%'>     (7)   4-methyl-2,5-dimethoxylamphetamine</p>

<p class=MsoNormal style='line-height:150%'>     (8)   Ibogaine</p>

<p class=MsoNormal style='line-height:150%'>     (9)   Lysergic acid
diethylamide</p>

<p class=MsoNormal style='line-height:150%'>     (10) Marihuana; except that on
and after the effective date of the &quot;New Jersey Cannabis Regulatory,
Enforcement Assistance, and Marketplace Modernization Act,&quot; P.L.2021, c.16
(C.24:6I-31 et al.), marihuana shall no longer be included in Schedule I, and
shall not be designated or rescheduled and included in any other schedule by
the director pursuant to the director's designation and rescheduling authority
set forth in section 3 of P.L.1970, c.226 (C.24:21-3).</p>

<p class=MsoNormal style='line-height:150%'>     (11) Mescaline</p>

<p class=MsoNormal style='line-height:150%'>     (12) Peyote</p>

<p class=MsoNormal style='line-height:150%'>     (13) N-ethyl-3-piperidyl
benzilate</p>

<p class=MsoNormal style='line-height:150%'>     (14) N-methyl-3-piperidyl
benzilate</p>

<p class=MsoNormal style='line-height:150%'>     (15) Psilocybin</p>

<p class=MsoNormal style='line-height:150%'>     (16) Psilocyn</p>

<p class=MsoNormal style='line-height:150%'>     (17) Tetrahydrocannabinols,
except when found in hemp or a hemp product cultivated, handled, processed,
transported, or sold pursuant to the &quot;New Jersey Hemp Farming Act,&quot;
P.L.2019, c.238 (C.4:28-6 et al.), or cannabis or a cannabis item, as those
terms are defined in section 3 of P.L.2021, c.16 (C.24:6I-33), that is grown,
cultivated, produced, or manufactured in accordance with the &quot;New Jersey
Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization
Act,&quot; P.L.2021, c.16 (C.24:6I-31 et al.).</p>

<p class=MsoNormal style='line-height:150%'>     <u>f. Illicit fentanyls.
Illicit fentanyls include any material, compound, mixture, or preparation that
is not listed as a controlled substance in Schedules I through V, is not a
Federal Food and Drug Administration (FDA) approved drug, and contains any
quantity of the following substances, their salts, isomers (whether optical,
positional, or geometric), homologues (analogs), and salts of isomers, and
homologues (analogs) unless specifically excepted whenever the existence of
these salts, isomers, homologues (analogs), and salts of isomers and homologues
(analogs) is possible within the specific chemical designations:i.  Furanyl
Fentanyl, with a chemical composition of
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furancarboxamide,
monohydrochloride or N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>ii.  3-Methylfentanyl, with
a chemical composition of
3-methyl-N-phenyl-N-[1-(2-phenethyl-4-piperidyl)-propanamide);</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>iii.  3-Methyl
Butyrylfentanyl, with a chemical composition of 3-Methyl,
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide, monohydrochloride;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>iv.  Valeryl Fentanyl, with
a chemical composition of
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide, monohydrochloride;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>v.  Norfentanyl, with a
chemical composition of N-phenyl-N-4-piperidinyl-propanamide;</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>vi. 
Para-Fluorobutyryl-Fentanyl, with a chemical composition of
N-(4-fluorophenyl)-N-[1-(2-phenylethyl) -4-piperidinyl]-butanamide,
monohydrochloride; and</u></p>

<p class=MsoNormal style='line-height:150%'>     <u>vii.  Carfentanyl, with a
chemical composition of 2-hydroxypropane-1, 2, 3-tricarboxylic acid; methyl
1-(2-phenylethyl)-4-(N-propanoylanilino) piperidine-4-carboxylateor.</u></p>

<p class=MsoNormal style='line-height:150%'>(cf: P.L.2021, c.16, s.44)</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     2.    This act shall take
effect immediately.</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal align=center style='text-align:center;line-height:150%'>STATEMENT</p>

<p class=MsoNormal style='line-height:150%'>&nbsp;</p>

<p class=MsoNormal style='line-height:150%'>     This bill would add illicit
fentanyls to Schedule I in the New Jersey Controlled Dangerous Substances
Act. Schedule I substances have high potential for abuse, and either have no
accepted medical use in treatment in the United States, or lack accepted safety
for use in treatment under medical supervision.  Illicit fentanyls are
derivatives of the regulated prescription drug fentanyl. In September 2016, the
Office of the Attorney General issued an emergency order that temporarily added
seven illicit fentanyls to Schedule I. On March 21, 2017 this designation was
made permanent, when these substances were added to Schedule I in the
Administrative Code (N.J.A.C. 13:45H-10.1.)  This bill would codify the
Schedule I placement of illicit fentanyls in the statutes.</p>

<p class=MsoNormal style='line-height:150%'>     This bill would not change the
designation of prescription fentanyl, which is a Schedule II substance.  A
substance is placed in Schedule II if it: (1) has high potential for abuse; (2)
has currently accepted medical use in treatment in the United States, or
currently accepted medical use with severe restrictions; and (3) abuse may lead
to severe psychic or physical dependence.           </p>

<p class=MsoNormal style='line-height:150%'>     Under subsection b. of N.J.S.A.2C:35-5,
unlawfully manufacturing, distributing, or dispensing any Schedule I or II
substance in a quantity of one ounce or more is a crime of the second degree
(punishable by a term of imprisonment of five to ten years or a fine up to
$150,000, or both).  Unlawfully manufacturing, distributing or dispensing in a
quantity of less than one ounce is a crime of the third degree (generally
punishable by a term of three to five years or a fine up to $15,000, or both,
but in this case also punishable by an increased fine of up to $75,000). </p>

<p class=MsoNormal style='line-height:150%'>     Specifically, the bill adds
the following substances to Schedule I:</p>

<p class=MsoNormal style='line-height:150%'>     Illicit fentanyls. Illicit fentanyls
include any material, compound, mixture, or preparation that is not listed as a
controlled substance in Schedules I through V, is not a Federal Food and Drug
Administration (FDA) approved drug, and contains any quantity of the following
substances, their salts, isomers (whether optical, positional, or geometric),
homologues (analogs), and salts of isomers, and homologues (analogs) unless
specifically excepted whenever the existence of these salts, isomers,
homologues (analogs), and salts of isomers and homologues (analogs) is possible
within the specific chemical designations:i.  Furanyl Fentanyl, with a chemical
composition of N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furancarboxamide,
monohydrochloride or N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide;</p>

<p class=MsoNormal style='line-height:150%'>     ii.  3-Methylfentanyl, with a
chemical composition of
3-methyl-N-phenyl-N-[1-(2-phenethyl-4-piperidyl)-propanamide);</p>

<p class=MsoNormal style='line-height:150%'>     iii.  3-Methyl
Butyrylfentanyl, with a chemical composition of 3-Methyl,
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide, monohydrochloride;</p>

<p class=MsoNormal style='line-height:150%'>     iv.  Valeryl Fentanyl, with a
chemical composition of
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide, monohydrochloride;</p>

<p class=MsoNormal style='line-height:150%'>     v.  Norfentanyl, with a
chemical composition of N-phenyl-N-4-piperidinyl-propanamide;</p>

<p class=MsoNormal style='line-height:150%'>     vi. 
Para-Fluorobutyryl-Fentanyl, with a chemical composition of
N-(4-fluorophenyl)-N-[1-(2-phenylethyl) -4-piperidinyl]-butanamide,
monohydrochloride; and</p>

<p class=MsoNormal style='line-height:150%'>     vii.  Carfentanyl, with a
chemical composition of 2-hydroxypropane-1, 2, 3-tricarboxylic acid; methyl 1-(2-phenylethyl)-4-(N-propanoylanilino)
piperidine-4-carboxylateor.</p>

</div>

</body>

</html>
